IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/11/2024 | $48.00 → $49.00 | Buy | H.C. Wainwright |
| 12/15/2023 | $41.00 | Buy | Jefferies |
| 12/4/2023 | $48.00 | Buy | H.C. Wainwright |
| 11/17/2023 | $43.00 | Buy | Truist |
| 10/31/2023 | $50.00 | Buy | Guggenheim |
| 10/25/2023 | $65.00 | Overweight | Piper Sandler |
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
EFFECT - Tourmaline Bio, Inc. (0001827506) (Filer)
S-3 - Tourmaline Bio, Inc. (0001827506) (Filer)
10-Q - Tourmaline Bio, Inc. (0001827506) (Filer)
8-K - Tourmaline Bio, Inc. (0001827506) (Filer)
8-K - Tourmaline Bio, Inc. (0001827506) (Filer)
8-K - Tourmaline Bio, Inc. (0001827506) (Filer)
8-K - Tourmaline Bio, Inc. (0001827506) (Filer)
10-Q - Tourmaline Bio, Inc. (0001827506) (Filer)
8-K - Tourmaline Bio, Inc. (0001827506) (Filer)
8-K - Tourmaline Bio, Inc. (0001827506) (Filer)
Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo's recent acquisition of AVTX-009, an anti-IL-1β mAb, and up to $185 million private placement financing WAYNE, Pa. and ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) today announced the addition of multiple biotech leaders to its Board of Directors. The Avalo Board brings together a team with expertise spanning finance, business operations, drug discovery and clinical development. "I am honored to announce these additions to our Board of Directors and welcome their operationa
NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. ("Tourmaline") (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that Clay Siegall, PhD, has been appointed as Chairman of the Board. "We are absolutely thrilled that Clay has joined Tourmaline as Chairman of the Board," said Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer of Tourmaline. "Clay built Seagen into one of the largest independent biotech companies in the world by taking a therapeutic concept and developing from it multiple successful medicines
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)
SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)
SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)
SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)
SC 13G - Tourmaline Bio, Inc. (0001827506) (Subject)
SC 13G - Tourmaline Bio, Inc. (0001827506) (Subject)
SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)
H.C. Wainwright reiterated coverage of Tourmaline with a rating of Buy and set a new price target of $49.00 from $48.00 previously
Jefferies initiated coverage of Tourmaline with a rating of Buy and set a new price target of $41.00
H.C. Wainwright resumed coverage of Tourmaline with a rating of Buy and set a new price target of $48.00
Truist initiated coverage of Tourmaline with a rating of Buy and set a new price target of $43.00
Guggenheim initiated coverage of Tourmaline with a rating of Buy and set a new price target of $50.00
Piper Sandler initiated coverage of Tourmaline with a rating of Overweight and set a new price target of $65.00
NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that it will host a virtual Investor Day on December 10, 2024, beginning at 10 a.m. ET. The event will include presentations from Tourmaline's leadership team and Dr. Marc Bonaca, a cardiologist and vascular medicine specialist serving as Executive Director of CPC Clinical Research and Professor of Medicine and William R. Hiatt Endowed Chair in Cardiovascular Research at the University of Colorado Anschutz.
– On track to report topline data from Phase 2 TRANQUILITY trial in first half of 2025 – – Assembled Cardiovascular Scientific Advisory Board (CV SAB), comprised of leading academic and industry experts, in October 2024 – – Showcased poster presentations at the American Society of Preventive Cardiology Annual Congress in August 2024 and the 19th Annual Cardiometabolic Health Congress in October 2024 – – Cash, cash equivalents and investments of $314.4 million as of September 30, 2024, providing cash runway into 2027 – NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a lat
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conferences: Truist Securities BioPharma Symposium, New YorkPanel: Close to Heart: Innovative Approaches to Targeting Cardiac & Skeletal Muscle IllnessesThursday, November 7, 2024 at 2:35 pm ET Guggenheim Securities Healthcare Innovation Conference, BostonFireside ChatTuesday, November 1
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that it will host a webinar, Understanding the Genetic Validation for IL-6 Inhibition in Cardiovascular Disease, featuring Dr. Dipender Gill, CEO and Founder of Sequoia Genetics. The webinar will be held on Friday, November 1, at 9:30 AM ET and will explore the latest advancements in leveraging human genetics to inform therapeutic strategies targeting IL-6 signaling pathways. Dr. Gill, a leader in leveragi
NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that it expects to present two posters at the upcoming 19th Annual Cardiometabolic Health Congress (CMHC), taking place October 17-19, 2024, in Boston, MA. These posters highlight Tourmaline's ongoing commitment to further characterizing inflammatory cardiovascular risk, as well as potential therapeutic mechanisms of IL-6 inhibition. Poster Presentations:Title: Utilization of High-Sensitivity C-Reacti
– Tourmaline assembles leading experts to support the development of pacibekitug for cardiovascular diseases – – Cardiovascular Scientific Advisory Board expected to provide strategic guidance as Tourmaline advances pacibekitug towards potential Phase 3 clinical trial readiness in 2025 for the treatment of cardiovascular diseases – NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the formation of its Cardiovascular Scientific Advisory Board
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, CEO, is expected to participate in the following investor conferences: H.C. Wainwright 26th Annual Global Investor Conference, New YorkFireside ChatMonday, September 9, 2024 at 12:00 pm ET Cantor Global Healthcare Conference, New YorkFireside ChatTuesday, September 17, 2024 at 3:40 pm ET A live webcast of both presentations will be available under "Events and Presentations"
– First patient dosed in May 2024 in Phase 2 TRANQUILITY trial evaluating pacibekitug (TOUR006) in patients with high cardiovascular risk – – On track to initiate a pivotal Phase 3 trial evaluating pacibekitug delivered subcutaneously every 8 weeks as first-line treatment for Thyroid Eye Disease (TED) in the second half of 2024 – – Added to the Russell 2000® Index and the broad-market Russell 3000® Index in June 2024 – – Cash, cash equivalents and investments of $334.4 million as of June 30, 2024, providing cash runway into 2027 – NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing t
Phase 2 TRANQUILITY trial is evaluating the high-sensitivity C-reactive protein (hs-CRP)-lowering effect, safety, tolerability, and pharmacokinetics (PK) of quarterly and monthly subcutaneous administration of TOUR006 in patients with chronic kidney disease and elevated hs-CRP — Dosing regimens are informed by six previous Phase 1 and Phase 2 clinical studies in healthy volunteers and patients with inflammatory autoimmune disorders, as well as PK/PD modeling —Topline data is expected first half of 2025 —Data from Phase 2 TRANQUILITY trial have the potential to advance TOUR006 toward Phase 3 readiness for atherosclerotic cardiovascular disease (ASCVD) and other cardiovascular diseases. NEW
NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the promotion of Ryan Robinson, CPA, to Chief Financial Officer and Treasurer, effective June 25, 2024. Mr. Robinson most recently held the role of Vice President, Finance and Controller at Tourmaline, in addition to serving as Tourmaline's Interim Chief Financial Officer and Treasurer since October 2023. "Ryan has been instrumental in Tourmaline's rapid growth over the last year, building a top-flight fin
HC Wainwright & Co. analyst Yi Chen reiterates Tourmaline Bio (NASDAQ:TRML) with a Buy and maintains $48 price target.
Truist Securities analyst Robyn Karnauskas reiterates Tourmaline Bio (NASDAQ:TRML) with a Buy and maintains $74 price target.
Shares of FactSet Research Systems Inc. (NYSE:FDS) fell sharply during Thursday’s session after the company reported worse-than-expected second-quarter revenue and issued FY24 guidance. FactSet Research posted adjusted earnings of $4.22 per share, beating market estimates of $3.88 per share. The company’s quarterly sales came in at $545.95 million, missing expectations of $546.80 million, according to data from Benzinga Pro. FactSet Research shares dipped 5.2% to $462.36 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Yield10 Bioscience, Inc. (NASDAQ:YTEN) shares jumped 136.7% to $0.5751 after the company announced that the USDA-APHIS Biotechnology
Gainers Yield10 Bioscience (NASDAQ:YTEN) shares moved upwards by 71.5% to $0.42 during Thursday's regular session. The market value of their outstanding shares is at $4.9 million. Monogram Orthopaedics (NASDAQ:MGRM) stock rose 28.74% to $2.15. The market value of their outstanding shares is at $68.0 million. As per the press release, Q4 earnings came out 4 days ago. X4 Pharmaceuticals (NASDAQ:XFOR) stock increased by 21.61% to $1.24. The market value of their outstanding shares is at $207.5 million. As per the news, the Q4 earnings report came out today. Eiger BioPharmaceuticals (NASDAQ:EIGR) shares rose 17.78% to $6.33. The market value of their outstanding shares is at $9.3 million. C
U.S. stocks traded higher this morning, with the Dow Jones index gaining around 200 points on Thursday. Following the market opening Thursday, the Dow traded up 0.52% to 39,718.37 while the NASDAQ rose 0.84% to 16,506.28. The S&P 500 also rose, gaining, 0.53% to 5,252.23. Check This Out: Micron, Accenture And 3 Stocks To Watch Heading Into Thursday Leading and Lagging Sectors Information technology shares rose by 0.9% on Thursday. In trading on Thursday, consumer staples shares fell by 0.1%. Top Headline U.S. initial jobless claims declined by 2,000 to 210,000 on the week ending March 16, versus market estimates of 215,000. Equities Trading UP Yield10 Bioscience,
Gainers Yield10 Bioscience (NASDAQ:YTEN) stock increased by 133.7% to $0.57 during Thursday's pre-market session. The market value of their outstanding shares is at $6.8 million. Immunovant (NASDAQ:IMVT) shares moved upwards by 14.0% to $35.99. The market value of their outstanding shares is at $5.2 billion. argenx (NASDAQ:ARGX) stock moved upwards by 13.24% to $404.22. The market value of their outstanding shares is at $23.9 billion. Virios Therapeutics (NASDAQ:VIRI) shares moved upwards by 11.79% to $0.39. The company's market cap stands at $7.5 million. Aspira Womens Health (NASDAQ:AWH) stock rose 10.79% to $3.85. The company's market cap stands at $39.7 million. CareMax (NASDAQ:CMA
U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Thursday. Shares of Five Below, Inc. (NASDAQ:FIVE) fell sharply in today’s pre-market trading after the company reported fourth-quarter financial results. Five Below reported quarterly earnings of $3.65 per share, up from $3.07 per share from the same period last year. Quarterly revenue clocked in at $1.34 billion, up from $1.12 billion year-over-year, according to data from Benzinga Pro. Five Below sees first-quarter earnings of between 58 cents and 69 cents per share and revenue in the range of $826 million to $846 million, based on opening approximately 55 to 60 new stores and assuming an